• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by OptimizeRx Corporation

    6/18/24 4:01:05 PM ET
    $OPRX
    Real Estate
    Real Estate
    Get the next $OPRX alert in real time by email
    S-8 1 ea0208056-s8_optimizerx.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on June 18, 2024

    Commission File No. 333-             

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

     

     

    OptimizeRx Corporation

    (Exact name of registrant as specified in its charter)

     

    Nevada   26-1265381
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)
         
    260 Charles Street, Suite 302, Waltham, MA   02453
    (Address of Principal Executive Offices)   (Zip Code)

     

    OptimizeRx Corporation

    2021 Equity Incentive Plan

    (Full title of the plan)

     

    Marion Odence-Ford, Esquire

    General Counsel

    OptimizeRx Corporation

    260 Charles Street

    Suite 302

    Waltham, MA 02453

    (248) 651-6568

    (Name and address of agent for service)

    (Telephone number, including area code, of agent for service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐  Accelerated filer ☐ 
    Non-accelerated filer ☒  Smaller reporting company ☒ 
        Emerging growth company ☐ 

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.      ☐

     

     

     

     

     

     

    REGISTRATION OF ADDITIONAL SHARES

    PURSUANT TO GENERAL INSTRUCTION E

     

    Pursuant to General Instruction E of Form S-8, the Registrant hereby makes the following statement: This Registration Statement on Form S-8 is being filed by the Registrant to register an additional 1,950,000 shares of its common stock which, pursuant to an amendment to the Registrant’s 2021 Equity Incentive Plan (the “Plan”), are issuable upon the grant, exercise or vesting of awards under the Plan. These 1,950,000 shares are in addition to the 2,500,000 shares of the Registrant’s common stock which were previously registered pursuant to the Registrant’s Registration Statement on Form S-8 (Commission File No. 333-259218) filed with the Securities and Exchange Commission (the “Commission”) on August 31, 2021 (the “Prior Registration Statement”). Pursuant to Instruction E of Form S-8, the contents of the Prior Registration Statement are hereby incorporated by reference.

     

    1

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, as filed with the Commission, are incorporated by reference into this Registration Statement by the Registrant:

     

    (a)the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed on April 15, 2024  (including information specifically incorporated by reference therein from the Registrant’s Definitive Proxy Statement on Schedule 14A, filed on April 29, 2024);

     

    (b)the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed on May 15, 2024;

     

    (c)the Registrant’s Current Reports on Form 8-K filed on January 5, 2024, January 26, 2024, April 2, 2024 (solely with respect to Item 1.01) and June 7, 2024.

     

    (d)the description of the Registrant’s Common Stock contained in the Registrant’s Current Report on Form 8-K filed on August 31, 2021.

     

    All documents filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part of this Registration Statement from the date of the filing of such documents.

     

    To the extent that any information contained in any Current Report on Form 8-K, or any exhibit thereto, is or was furnished to, rather than filed with, the Commission, such information or exhibit is specifically not incorporated by reference.

     

    II-1

     

     

    Item 8. Exhibits.

     

    The following exhibits are filed as part of this Registration Statement or, where so indicated have been previously filed and are incorporated herein by reference.

     

    Exhibit   Description of Exhibit
    4.1   Articles of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Registration Statement on Form S-1, as filed with the Commission on November 12, 2008).
    4.2   Certificate of Correction of the Registrant, dated April 30, 2018 (incorporated by reference to Exhibit 3.5 of the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as filed with the Commission on March 12, 2019).
    4.3   Third Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 of the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Commission on March 10, 2023).
    4.4   OptimizeRx Corporation 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K, as filed with the Commission on August 25, 2021).
    4.5   Amendment No. 1 to the OptimizeRx 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K, as filed with the Commission on June 7, 2024).
    5.1   Opinion of The Doney Law Firm.
    23.1   Consent of UHY LLP.
    23.2   Consent of The Doney Law Firm (included in Exhibit 5.1).
    24.1   Power of Attorney (included on the signature page of this Registration Statement).
    107.1   Filing Fee table.

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts on June 18, 2024.

     

      OptimizeRx Corporation
       
      By: /s/ William J. Febbo
      Name:  William J. Febbo
      Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    We, the undersigned officers and directors of OptimizeRx Corporation, hereby severally constitute and appoint William Febbo and Edward Stelmakh, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities held on the dates indicated.

     

    Signature   Title   Date
             
    /s/ William J. Febbo   Chief Executive Officer and Director   June 18, 2024
    William J. Febbo   (Principal Executive Officer)    
             
    /s/ Edward Stelmakh   Chief Financial Officer and Chief Operations Officer   June 18, 2024
    Edward Stelmakh   (Principal Financial and Accounting Officer)    
             
    /s/ Lynn O’Connor Vos   Director, Chairperson   June 18, 2024
    Lynn O’Connor Vos        
             
    /s/ James Lang   Director   June 18, 2024
    James Lang        
             
    /s/ Patrick Spangler   Director   June 18, 2024
    Patrick Spangler        
             
    /s/ Gregory D. Wasson   Director   June 18, 2024
    Gregory D. Wasson         
             
    /s/ Catherine M. Klema    Director   June 18, 2024
    Catherine M. Klema         

     

     

    II-3

     

    Get the next $OPRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPRX

    DatePrice TargetRatingAnalyst
    1/8/2025$7.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    12/20/2024$5.50Equal-Weight
    Stephens
    7/25/2024$18.50Buy
    B. Riley Securities
    4/4/2024$15.00Mkt Outperform
    JMP Securities
    1/3/2024$15.00Equal Weight
    Barclays
    2/2/2023$30.00Buy
    B. Riley Securities
    11/1/2022$19.00Buy
    Stifel
    7/15/2022$38.00Outperform
    SVB Leerink
    More analyst ratings

    $OPRX
    SEC Filings

    View All

    SEC Form 10-Q filed by OptimizeRx Corporation

    10-Q - OptimizeRx Corp (0001448431) (Filer)

    11/7/25 4:03:16 PM ET
    $OPRX
    Real Estate

    OptimizeRx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - OptimizeRx Corp (0001448431) (Filer)

    11/6/25 4:13:14 PM ET
    $OPRX
    Real Estate

    SEC Form SCHEDULE 13G filed by OptimizeRx Corporation

    SCHEDULE 13G - OptimizeRx Corp (0001448431) (Subject)

    10/31/25 11:03:55 AM ET
    $OPRX
    Real Estate

    $OPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    OptimizeRx downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded OptimizeRx from Outperform to Sector Perform and set a new price target of $6.00 from $7.00 previously

    1/8/25 8:17:01 AM ET
    $OPRX
    Real Estate

    Stephens initiated coverage on OptimizeRx with a new price target

    Stephens initiated coverage of OptimizeRx with a rating of Equal-Weight and set a new price target of $5.50

    12/20/24 7:46:38 AM ET
    $OPRX
    Real Estate

    B. Riley Securities resumed coverage on OptimizeRx with a new price target

    B. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $18.50

    7/25/24 8:24:56 AM ET
    $OPRX
    Real Estate

    $OPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET

    WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter period ended December 31, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date: Thursday, March 5, 2026 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific T

    2/5/26 8:00:00 AM ET
    $OPRX
    Real Estate

    OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing

    WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life science companies reach and engage healthcare professionals (HCPs) and patients, today announced at CES 2026 a data collaboration with Experian, a leading global data and technology company. This integration maps OptimizeRx Micro-Neighborhood® audiences to Experian's identity graph, enabling seamless onboarding and curated audience activation, delivering a transparent, reliable methodology for life sciences brands and healthcare marketing agencies to reach and measure consumer audiences at scale. Addressing Fragmentation that

    1/7/26 8:00:00 AM ET
    $OPRX
    Real Estate

    OptimizeRx Continues Expansion of the Company's Point-Of-Care Network

    WALTHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced four new partner agreements that meaningfully expand the Company's in-workflow point-of-care (POC) network, fortify its long-term competitive position, and increase total National Provider Identifier (NPI) reach. The newly executed agreements include: An exclusive, multi-year agreement with a high-demand e-prescribing (eRx) platform previously available only through a competitive networkA new partnership that extends the Company'

    12/17/25 4:30:00 AM ET
    $OPRX
    Real Estate

    $OPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Executive Officer Silvestro Stephen L covered exercise/tax liability with 3,361 shares, decreasing direct ownership by 2% to 190,507 units (SEC Form 4)

    4/A - OptimizeRx Corp (0001448431) (Issuer)

    12/23/25 5:43:26 PM ET
    $OPRX
    Real Estate

    Chief Commercial Officer Greco Theresa covered exercise/tax liability with 1,420 shares, decreasing direct ownership by 2% to 72,868 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    12/23/25 4:55:22 PM ET
    $OPRX
    Real Estate

    Chief Executive Officer Silvestro Stephen L covered exercise/tax liability with 3,361 shares, decreasing direct ownership by 2% to 190,507 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    12/23/25 4:54:50 PM ET
    $OPRX
    Real Estate

    $OPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lang James Paul bought $2,443,761 worth of shares (321,408 units at $7.60), increasing direct ownership by 472% to 389,452 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    3/19/25 7:40:24 PM ET
    $OPRX
    Real Estate

    CEO Febbo William J bought $100,220 worth of shares (20,000 units at $5.01), increasing direct ownership by 3% to 601,253 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    12/16/24 2:28:39 PM ET
    $OPRX
    Real Estate

    $OPRX
    Leadership Updates

    Live Leadership Updates

    View All

    OptimizeRx Partners with Lamar Advertising to Reach Clinically Relevant Audiences Through Out-of-Home Healthcare Advertising

    Strategic Partnership Combines OptimizeRx's Patented Micro-Neighborhood® Targeting Data with Lamar's Vast Nationwide OOH Network to Strengthen OOH Media for Healthcare Marketing WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- OptimizeRx (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, and Lamar Advertising Company (NASDAQ:LAMR), one of the largest out-of-home (OOH) advertising companies in North America, today announced a strategic partnership to revolutionize OOH advertising for pharmaceutical and healthcare brands. Through this collaboration, OptimizeRx's

    9/9/25 4:05:00 PM ET
    $LAMR
    $OPRX
    Real Estate Investment Trusts
    Real Estate

    OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth

    WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced organizational updates and leadership advancements designed to accelerate the Company's Rule of 40 strategy—balancing sustained growth with increased profitability. These changes reflect the strength of the Company's leadership bench and CEO Steve Silvestro's commitment to aligning talent and structure with OptimizeRx's long-term strategic objectives under his management. "Over the past six months, I have had the opportunity to ev

    8/19/25 7:30:00 AM ET
    $OPRX
    Real Estate

    Paynela Appoints Healthcare Technology Veteran William Febbo to Board of Directors

    Former OptimizeRX CEO Brings Extensive Digital Health and Pharmaceutical Patient Assistance Expertise to AI-Driven Healthcare Financing Company Paynela, a leading healthcare financing company revolutionizing claim processing through artificial intelligence that leverages AI advancements to process thousands of medical claims in under a minute, today announced the appointment of William Febbo to its Board of Directors, effective immediately. Febbo brings over 30 years of experience in healthcare technology, digital health innovation, and pharmaceutical patient assistance programs to the rapidly growing company. From 2016 to 2025, Febbo served as Chief Executive Officer and Director of Op

    7/30/25 12:00:00 PM ET
    $OPRX
    Real Estate

    $OPRX
    Financials

    Live finance-specific insights

    View All

    OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET

    WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter period ended December 31, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date: Thursday, March 5, 2026 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific T

    2/5/26 8:00:00 AM ET
    $OPRX
    Real Estate

    OptimizeRx Reports Third Quarter 2025 Financial Results and Increases Fiscal Year 2025 Guidance

    -   Q3 revenue of $26.1 million, increased 22% year-over-year-   Q3 gross profit increased 30% year-over-year to $17.5 million-   Increases full year 2025 guidance to a revenue range between $105 million and $109 million and adjusted EBITDA range between $16 million and $19 million-   Introduces 2026 guidance with a revenue range between $118 million and $124 million and adjusted EBITDA range between $19 million and $22 million-   Paid off an incremental $2 million in principal from term loan subsequent to the end of Q3 WALTHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life scie

    11/6/25 4:01:00 PM ET
    $OPRX
    Real Estate

    OptimizeRx Sets Third Quarter 2025 Conference Call for November 6, 2025, at 4:30 p.m. ET

    WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, November 6, 2025, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Thursday, November 6, 2025Time:4:30 p.m. Eastern Time (1:30 p.m. Pacifi

    10/20/25 8:00:00 AM ET
    $OPRX
    Real Estate

    $OPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

    SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

    12/6/24 4:26:03 PM ET
    $OPRX
    Real Estate

    SEC Form SC 13G filed by OptimizeRx Corporation

    SC 13G - OptimizeRx Corp (0001448431) (Subject)

    11/14/24 3:18:35 PM ET
    $OPRX
    Real Estate

    Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

    SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

    11/14/24 11:25:34 AM ET
    $OPRX
    Real Estate